SAMANTA FUNES

Prof. SAMANTA FUNES

IMIBIO-SL, CONICET
+1

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2018 in Immunology
Verified
Journal Article
Closed access
PDF file
SFSAMANTA FUNES
SAMANTA FUNES
MRMariana Rios
Mariana Rios
JEJorge Escobar‐Vera
Jorge Escobar‐Vera
AKAlexis Kalergis
Alexis Kalergis

23 July 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SFSAMANTA FUNES
SAMANTA FUNES
MRMariana Rios
Mariana Rios
AFAyleen Fernández-Fierro
Ayleen Fernández-Fierro
CCCamila Covián
Camila Covián
SBSusan M. Bueno
Susan M. Bueno
AKAlexis Kalergis
Alexis Kalergis
Heme oxygenase (HO) is the primary antioxidant enzyme involved in heme group degradation. A variety of stimuli triggers the expression of the inducible HO-1 isoform, which is modulated by its substrate and cellular stressors. A major anti-inflammatory role has been assigned to the HO-1 activity. Therefore, in recent years HO-1 induction has been employed as an approach to treating several disorders displaying some immune alterations components, such as exacerbated inflammation or self-reactivity. Many natural compounds have shown to be effective inductors of HO-1 without cytotoxic effects; among them, most are chemicals present in plants used as food, flavoring, and medicine. Here we discuss some naturally derived compounds involved in HO-1 induction, their impact in the immune response modulation, and the beneficial effect in diverse autoimmune disorders. We conclude that the use of some compounds from natural sources able to induce HO-1 is an attractive lifestyle toward promoting human health. This review opens a new outlook on the investigation of naturally derived HO-1 inducers, mainly concerning autoimmunity.

1 April 2019 in Autoimmunity Reviews
Verified
Journal Article
Closed access
SFSAMANTA FUNES
SAMANTA FUNES
ALAmaranta Manrique de Lara
Amaranta Manrique de Lara
MAMaría J. Altamirano-Lagos
María J. Altamirano-Lagos
JMJuan Pablo Mackern-Oberti
Juan Pablo Mackern-Oberti
JEJorge Escobar-Vera
Jorge Escobar-Vera
AKAlexis Kalergis
Alexis Kalergis

7 October 2019 in Immunology
Verified
Journal Article
Closed access
PDF file
SFSAMANTA FUNES
SAMANTA FUNES
MRMariana Ríos
Mariana Ríos
FGFelipe Gómez‐Santander
Felipe Gómez‐Santander
AFAyleen Fernández‐Fierro
Ayleen Fernández‐Fierro
MAMaría J. Altamirano‐Lagos
María J. Altamirano‐Lagos
AKAlexis Kalergis
Alexis Kalergis

Verified
Journal Article
Open access
PDF file
AFAyleen Fernández-Fierro
Ayleen Fernández-Fierro
SFSAMANTA FUNES
SAMANTA FUNES
MRMariana Rios
Mariana Rios
CCCamila Covián
Camila Covián
JGJorge González
Jorge González
AKAlexis Kalergis
Alexis Kalergis
The heme oxygenase (HO) system involves three isoforms of this enzyme, HO-1, HO-2, and HO-3. The three of them display the same catalytic activity, oxidating the heme group to produce biliverdin, ferrous iron, and carbon monoxide (CO). HO-1 is the isoform most widely studied in proinflammatory diseases because treatments that overexpress this enzyme promote the generation of anti-inflammatory products. However, neonatal jaundice (hyperbilirubinemia) derived from HO overexpression led to the development of inhibitors, such as those based on metaloproto- and meso-porphyrins inhibitors with competitive activity. Further, non-competitive inhibitors have also been identified, such as synthetic and natural imidazole-dioxolane-based, small synthetic molecules, inhibitors of the enzyme regulation pathway, and genetic engineering using iRNA or CRISPR cas9. Despite most of the applications of the HO inhibitors being related to metabolic diseases, the beneficial effects of these molecules in immune-mediated diseases have also emerged. Different medical implications, including cancer, Alzheimer´s disease, and infections, are discussed in this article and as to how the selective inhibition of HO isoforms may contribute to the treatment of these ailments.

1 September 2012 in Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology
Verified
Journal Article
Closed access
JCJuan Chediack
Juan Chediack
SFSAMANTA FUNES
SAMANTA FUNES
FCFabricio Damián Cid
Fabricio Damián Cid
VFVerónica Filippa
Verónica Filippa
ECEnrique Caviedes-Vidal
Enrique Caviedes-Vidal